Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-5836 in advanced breast cancer and solid tumors
NCT05759949Phase 1Completed
- Sponsor
- Relay Therapeutics
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RLY-5836 in breast cancer and solid tumor (5 arms), sponsored by Relay Therapeutics. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose up to 24 months and 3 more. Started Mar 2023; status: completed.
02
Drugs
RLY-5836
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05759949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759949.